Liu Han, Cen Xi, Suo Tao, Cai Xueya, Yuan Xuewen, Shen Sheng, Liu Houbao, Li Yue
Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Department of Public Health Sciences, Division of Health Policy and Outcomes Research, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420644, Rochester, NY, 14642, USA.
World J Surg. 2017 Feb;41(2):525-537. doi: 10.1007/s00268-016-3733-5.
This population-based study examined surgical outcomes and hospital and post-acute care resource use after operations of cholangiocarcinoma during 2005-2012.
Using New York State hospital claims, we identified subjects with intrahepatic tumor who underwent hepatectomy only (n = 2089), subjects with perihilar tumor who underwent hepatectomy and biliary-enteric anastomosis (BEA; n = 389) or BEA only (n = 3721), and subjects with distal cholangiocarcinoma undergoing pancreatectomy or pancreaticoduodenectomy (n = 228). We performed trend analyses for each group and calculated overall risk-adjusted mortality, complication, and 30-day readmission rates for hospitals using multivariable logistic regressions.
Mortality rate was roughly 12 % over years for perihilar cases undergoing hepatectomy and BEA, significantly higher than the rates of other 3 groups (p = 0.000). The overall complication rate was 40 % for subjects undergoing both hepatectomy and BEA, more than doubling the rate for subjects undergoing hepatectomy or BEA alone (p = 0.000). Average LOS declined markedly for perihilar cases undergoing hepatectomy and BEA (from 21 days in 2005 to 16 days in 2012) and subjects with distal cholangiocarcinoma (from 22 days in 2005 to 16 days in 2012), but other outcomes did not change dramatically. Risk-adjusted hospital outcome rates varied substantially.
Surgical patients with cholangiocarcinoma incur considerable mortality, postoperative complications, and resource uses, especially among those undergoing hepatectomy and BEA for perihilar tumors.
这项基于人群的研究调查了2005年至2012年间胆管癌手术后的手术结果以及医院和急性后期护理资源的使用情况。
利用纽约州医院的索赔数据,我们确定了仅接受肝切除术的肝内肿瘤患者(n = 2089)、接受肝切除术和胆肠吻合术(BEA;n = 389)或仅接受BEA的肝门部肿瘤患者(n = 3721),以及接受胰腺切除术或胰十二指肠切除术的远端胆管癌患者(n = 228)。我们对每组进行了趋势分析,并使用多变量逻辑回归计算了医院的总体风险调整死亡率、并发症发生率和30天再入院率。
多年来,接受肝切除术和BEA的肝门部病例的死亡率约为12%,显著高于其他三组的死亡率(p = 0.000)。接受肝切除术和BEA的患者的总体并发症发生率为40%,比仅接受肝切除术或BEA的患者的发生率高出一倍多(p = 0.000)。接受肝切除术和BEA的肝门部病例的平均住院时间显著下降(从2005年的21天降至2012年的16天),远端胆管癌患者的平均住院时间也显著下降(从2005年的22天降至2012年的16天),但其他结果没有显著变化。风险调整后的医院结局率差异很大。
胆管癌手术患者面临相当高的死亡率、术后并发症和资源使用,尤其是那些接受肝门部肿瘤肝切除术和BEA的患者。